— Know what they know.
Not Investment Advice

CTIC NASDAQ

CTI BioPharma Corp.
1W: +0.2% 1M: +1.1% 3M: +111.4% 1Y: +52.3% 3Y: +615.8% 5Y: +80.7%
$9.10
Last traded 2023-06-23 — delisted
NASDAQ · Healthcare · Biotechnology · $1.2B mcap · 100M float · 6.36% daily turnover

Cash Flow Trends

Operating Cash Flow
-$81M +4.4% ▲
Capital Expenditures
$25M +0.0% ▲
5Y CAGR: +248.0%
Free Cash Flow
-$106M -25.1% ▼
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
-$35M -239.8% ▼

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2018FY2019FY2020FY2021FY2022
— Operating Activities —
Net Income-$29M-$40M-$52M-$98M-$93M
Depreciation & Amort.$593K$546K$532K$526K$2M
Stock-Based Comp.$0$5M$4M$5M$10M
Change in Working Capital-$13M$8M-$2M$8M-$8M
Other Non-Cash Items-$4M$59K$4M-$113K$8M
Operating Cash Flow-$40M-$28M-$42M-$85M-$81M
— Investing Activities —
Capital Expenditures-$33K$0-$17K$0-$25M
Acquisitions (Net)$0$0$0$0$25M
Investment Purchases-$42M-$11M-$12M$0-$89M
Investment Sales$12M$39M$2M$12M$40M
Other Investing$0$0$0$0-$25M
Investing Cash Flow-$30M$28M-$10M$12M-$74M
— Financing Activities —
Net Debt Issuance$0$0$0$0$0
Stock Repurchased$0$0$0$0$0
Dividends Paid$0$0$0$0$0
Other Financing$63M-$6M$61M$98M$120M
Financing Cash Flow$63M-$6M$61M$98M$120M
Net Change in Cash-$7M-$5M$9M$25M-$35M
Cash End of Period$36M$31M$40M$65M$30M
Free Cash Flow-$40M-$28M-$42M-$85M-$106M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms